Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-26 @ 10:43 PM
Ignite Modification Date: 2025-12-26 @ 10:43 PM
NCT ID: NCT05161312
Eligibility Criteria: Inclusion Criteria: * Signed written informed consent. * Age ≥ 18 years * Ability to read and write in Romanian * History of histologically or cytologically confirmed breast cancer * An interval of \< 24 months from histologically or cytologically confirmed breast cancer * Ongoing curative cancer treatment * Ongoing regular psychoactive medication only accepted if dosage has been stable during the last 3 months * Daily access to the Internet by computer and/or smartphone * Ability to use a computer and/or smartphone and the internet * No participation on any other interventional study or clinical trial Exclusion Criteria: * Age ≤ 18 years * Inability to co-operate and give informed consent * Breast cancer not histologically or cytologically confirmed * History of other malignancy within the last 5 years * Current severe, uncontrolled systemic disease or mental disorder * Absence of clinically significant symptoms * Parallel ongoing psychological treatment * Ongoing regular psychoactive medication if dosage has been changed during the last 3 months * No access to the internet * Inability to use a computer and/or smartphone and the internet * Parallel ongoing participation in other interventional study or clinical trial * Assessment by the investigator to be unable or unwilling to comply with the requirements of the protocol
Healthy Volunteers: False
Sex: FEMALE
Minimum Age: 18 Years
Maximum Age: 80 Years
Study: NCT05161312
Study Brief:
Protocol Section: NCT05161312